Literature DB >> 3069480

A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria.

J Karbwang1, D J Back, D Bunnag, A M Breckenridge.   

Abstract

We have studied the kinetics of a single oral dose of mefloquine (750 mg) in 12 Thai patients with falciparum malaria and have compared the results with those of a previous study in 12 healthy Thai volunteers. All the patients responded to treatment with a mean parasite clearance time of 66.6 h and a mean fever clearance time of 54.1 h. There was no significant difference in peak plasma concentration, time to peak, area under the curve or apparent volume of distribution between patients and controls. However, the terminal half-life (t1/2) and mean residence time (MRT) were shorter in the patients (12.2 vs 16.7 days for t1/2 and 15.5 vs 21.4 days for MRT). We conclude that there are changes in the disposition of mefloquine related to malaria, although the exact basis of the changes is not clear.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3069480     DOI: 10.1007/bf00637607

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Single dose kinetics of mefloquine in man. Plasma levels of the unchanged drug and of one of its metabolites.

Authors:  D E Schwartz; G Eckert; D Hartmann; B Weber; D Richard-Lenoble; J M Ekue; M Gentilini
Journal:  Chemotherapy       Date:  1982       Impact factor: 2.544

2.  Studies of the disposition and metabolism of mefloquine HCl (WR 142,490), a quinolinemethanol antimalarial, in the rat. Limited studies with an analog, WR 30,090.

Authors:  J Y Mu; Z H Israili; P G Dayton
Journal:  Drug Metab Dispos       Date:  1975 May-Jun       Impact factor: 3.922

3.  An open, randomized, phase III clinical trial of mefloquine and of quinine plus sulfadoxine-pyrimethamine in the treatment of symptomatic falciparum malaria in Brazil.

Authors:  J M de Souza; U K Sheth; R M de Oliveira; H Roulet; S D de Souza
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

4.  Studies of mefloquine bioavailability and kinetics using a stable isotope technique: a comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers.

Authors:  S Looareesuwan; N J White; D A Warrell; I Forgo; U G Dubach; U B Ranalder; D E Schwartz
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

5.  A phase I clinical trial of mefloquine in Brazilian male subjects.

Authors:  J M de Souza
Journal:  Bull World Health Organ       Date:  1983       Impact factor: 9.408

6.  A phase II clinical trial of mefloquine in Brazilian male subjects.

Authors:  J M de Souza
Journal:  Bull World Health Organ       Date:  1983       Impact factor: 9.408

7.  The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism.

Authors:  J H Rivière; D J Back; A M Breckenridge; R E Howells
Journal:  Br J Clin Pharmacol       Date:  1985-11       Impact factor: 4.335

8.  The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects.

Authors:  J Karbwang; D Bunnag; A M Breckenridge; D J Back
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand.

Authors:  T Harinasuta; D Bunnag; W H Wernsdorfer
Journal:  Bull World Health Organ       Date:  1983       Impact factor: 9.408

  9 in total
  14 in total

1.  Effect of ampicillin on mefloquine pharmacokinetics in Thai males.

Authors:  J Karbwang; K Na Bangchang; D J Back; D Bunnag
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment.

Authors:  B G Charles; A Blomgren; P E Nasveld; S J Kitchener; A Jensen; R M Gregory; B Robertson; I E Harris; M P Reid; M D Edstein
Journal:  Eur J Clin Pharmacol       Date:  2007-01-11       Impact factor: 2.953

3.  Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers.

Authors:  M D Edstein; D A Kocisko; T G Brewer; D S Walsh; C Eamsila; B G Charles
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

4.  Investigation of the in vitro gender-specific partitioning of mefloquine in malarial infected red blood cells and plasma.

Authors:  Nongluk Seethorn; Walther H Wernsdorfer; Harald Noedl; Juntra Karbwang; Kesara Na-Bangchang
Journal:  Am J Trop Med Hyg       Date:  2013-09-03       Impact factor: 2.345

Review 5.  Clinical pharmacokinetics of mefloquine.

Authors:  J Karbwang; N J White
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

6.  Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria.

Authors:  J Karbwang; K A Milton; K Na Bangchang; S A Ward; G Edwards; D Bunnag
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

7.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

Review 8.  Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  K J Palmer; S M Holliday; R N Brogden
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

9.  Mefloquine pharmacokinetics and resistance in children with acute falciparum malaria.

Authors:  F Nosten; F ter Kuile; T Chongsuphajaisiddhi; K Na Bangchang; J Karbwang; N J White
Journal:  Br J Clin Pharmacol       Date:  1991-05       Impact factor: 4.335

10.  Pharmacokinetics of mefloquine in combination with sulfadoxine-pyrimethamine and primaquine in male Thai patients with falciparum malaria.

Authors:  J Karbwang; D J Back; D Bunnag; A M Breckenridge
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.